ClinicalTrials.gg
RecruitingNCT06282042EMCAMIUpdated Oct 20, 2025

Early Transcatheter Mitral Valve Repair After Myocardial Infarction

An interventional study of Early transcatheter edge-to-edge mitral valve repair (TEER). and MitraClip in Acute Mitral Regurgitation, sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias. Recruiting at 32 sites in 4 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Fundación para la Investigación Biosanitaria del Principado de Asturias · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Mitral Valve Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Mitral Valve Insufficiency · Spain.

Planned enrollment
6th of 12
250 · median 204
Started
2024
with 2 others
No phase
11 of 20
7 open now
Primary completion
2027-06
later than 7 of 14 live
Registered
15th of 20
by date
Lead sponsor
1 of 20
Fundación para la Investigación Biosanitaria del Principado de Asturias

Among the 20 studies in Mitral Valve Insufficiency with a site in Spain, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2024, is one of 11 with no phase, reaches primary completion later than 7 of the 14 other live ones, and was the 15th registered.

Mitral Valve Insufficiency

471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.

Browse Mitral Valve Insufficiency studies →

Open to participants now

11 of the 20 studies in Mitral Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Mitral Valve Insufficiency with a site in Spain, or all of them as a file.
02

Study summary

To explore the impact of early transcatheter edge-to-edge repair of acute functional mitral regurgitation after myocardial infarction on the combined incidence of death and heart-failure associated hospitalisations at one-year follow-up, and quality of life and LV remodelling at two-year follow-up.

Read the detailed description

Prospective, multicentre, randomised, open-label, comparative effectiveness clinical trial for the treatment of clinically significant functional mitral regurgitation within 60 days after acute myocardial infarction, who are treated per standard of care and who have been determined by the site's local heart team as inappropriate or too high risk for mitral valve surgery.

Eligible subjects will be randomized in a 1:1 ratio to the MitraClip device (intervention group) or to no MitraClip device (Control group).

03

Conditions studied

  • Acute Mitral Regurgitation

Keywords

  • MitraClip
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with symptomatic moderate to severe or severe MR after acute MI
  • Age > 18 years
  • Based on the following classification recently published in "Transcatheter Mitral Edge-to-Edge Repair for Treatment of Acute Mitral Regurgitation" by M. Shuvy et al. (Can J Cardiol. 2023) patients will be included if categorized in Type 2, 3 or 4:

Exclusion criteria

Exclusion Criteria:

  • Primary MR (e.g. papillary muscle rupture)
  • EF ≤ 25%
  • Accepted for CABG
  • Presence of cardiogenic shock (AMR type 1)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    TEER + OMT

    Early transcatheter edge-to-edge mitral valve repair (TEER) plus optimal medical treatment

    Procedure: Early transcatheter edge-to-edge mitral valve repair (TEER). · Device: MitraClip · Other: Optimal medical treatment

  • Other
    OMT

    Optimal medical treatment

    Other: Optimal medical treatment

Interventions

  • ProcedureEarly transcatheter edge-to-edge mitral valve repair (TEER).

    TEER will be planned and performed as soon as possible, but within 60 days after index myocardial infarction, and within 30 days of randomisation using the MitraClip device.

  • DeviceMitraClip

    MitraClip

  • OtherOptimal medical treatment

    Optimal medical treatment

06

What researchers measure

Primary outcomes

  1. All-cause death or Cumulative Heart Failure hospitalizations

    Composite of 1. All-cause death 2. Cumulative Heart Failure hospitalizations

    Time frame: 12 months

07

Study locations

2 of 32 sites recruiting
  • Emek Medical Center
    Afula, Afula 1834111, Israel
    Not yet recruiting
  • Shaare Zedek Medical Center
    Jerusalem, Jerusalen 9103102, Israel
    Recruiting
    • Mony Shuvy · Contact
    • Dr. Mony Shuvy · Principal investigator
  • Rabin Medical Center
    Petah Tikva, Petah Tikva 4941492, Israel
    Not yet recruiting
    • Leor Perl · Contact
    • Dr. Leor Perl · Principal investigator
  • Sheba Medical Center
    Ramat Gan, Ramat Gan, Israel
    Not yet recruiting
    • Paul Fefer · Contact
    • Dr. Paul Fefer · Principal investigator
  • Civil Hospital of Brescia
    Brescia, Brescia 25123, Italy
    Not yet recruiting
    • Marianna Adamo · Contact
    • Dra. Marianna Adamo · Principal investigator
  • Ospedale Policlinico San Martino
    Genova, Genova 16132, Italy
    Not yet recruiting
  • San Raffaele Hospital
    Milan, Milano 20132, Italy
    Not yet recruiting
    • Cosmo Godino · Contact
    • Dr. Cosmo Godino · Principal investigator
    • Dr. Francesco Maisano · Principal investigator
  • Centro Cardiológico Monzino
    Milan, Milan 20138, Italy
    Not yet recruiting
  • Policlínico San Donato
    San Donato Milanese, San Donato Milanese 20097, Italy
    Not yet recruiting
    • Francesco Bedogni · Contact
    • Dr. Francesco Bedogni · Principal investigator
  • Amsterdam University Medical Center
    Amsterdam, Amsterdam 1081 HV, Netherlands
    Not yet recruiting
    • R. Delewi · Contact
    • Dr. R. Delewi · Principal investigator
  • Amphia Hospital
    Breda, Breda 4818 CK, Netherlands
    Not yet recruiting
    • B. van der Branden · Contact
    • Dr. B. van der Branden · Principal investigator
  • Catharina Ziekenhuis Hospital
    Eindhoven, Eindhoven 5623 EJ, Netherlands
    Not yet recruiting
    • P. Tonino · Contact
    • Dr. P. Tonino · Principal investigator
  • Leiden University Medical Center
    Leiden, Leiden 2333 ZA, Netherlands
    Not yet recruiting
    • F. van der Kley · Contact
    • Dr. F. van der Kley · Principal investigator
  • Maastricht University Medical Center
    Maastricht, Maastricht 6229 HX, Netherlands
    Not yet recruiting
    • P.A. Vriesendorp · Contact
    • Dr. P.A. Vriesendorp · Principal investigator
  • St. Antonius Hospital
    Nieuwegein, Nieuwegein 3435 CM, Netherlands
    Not yet recruiting
    • L. Timmers · Contact
    • Dr. L. Timmers · Principal investigator
  • Erasmus University Medical Center
    Rotterdam, Rotterdam 3015 GD, Netherlands
    Not yet recruiting
    • N. van Mieghem · Contact
    • Dr. N. van Mieghem · Principal investigator
  • Isala Hospital
    Zwolle, Zwolle 8025 AB, Netherlands
    Not yet recruiting
    • R. Hermanides · Contact
    • Dr. R. Hermanides · Principal investigator
  • Hospital General Universitario Dr. Balmis
    Alicante, Alicante 03010, Spain
    Not yet recruiting
    • José Valencia Martín, MD, PhD · Contact
    • José Valencia Martín, MD, PhD · Principal investigator
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Barcelona 08025, Spain
    Not yet recruiting
    • Dabit Arzamendi, MD, PhD · Contact
    • Dabit Arzamendi, MD, PhD · Principal investigator
  • Hospital Universitario Vall d'Hebrón
    Barcelona, Barcelona 08035, Spain
    Not yet recruiting
    • Bruno García del Blanco, MD, PhD · Contact
    • Dr. Bruno García del Blanco, MD, PhD · Principal investigator
  • Hospital Clínic Barcelona
    Barcelona, Barcelona 08036, Spain
    Not yet recruiting
    • Xavier Freixa Rofastes, MD, PhD · Contact
    • Dr. Xavier Freixa Rofastes, MD, PhD · Principal investigator
  • Hospital Universitario de Bellvitge
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
    Not yet recruiting
  • Hospital Universitario Marqués de Valdecilla
    Santander, Cantabria 39008, Spain
    Not yet recruiting
    • Jose María de la Torre, MD, PhD · Contact
    • Dr. Jose María de la Torre, MD, PhD · Principal investigator
  • Hospital Universitario Reina Sofía
    Córdoba, Córdoba 14004, Spain
    Not yet recruiting
    • Manuel Pan Álvarez, MD, PhD · Contact
    • Dr. Manuel Pan Álvarez, MD, PhD · Principal investigator
  • Hospital Universitario Doctor Negrin
    Las Palmas de Gran Canaria, Las Palmas 35010, Spain
    Not yet recruiting
    • Pedro Martín, MD, PhD · Contact
    • Dr. Pedro Martín, MD, PhD · Principal investigator
  • Hospital Universitario Ramón y Cajal
    Madrid, Madrid 28034, Spain
    Not yet recruiting
    • Ángel Sánchez-Recalde, MD, PhD · Contact
    • Dr. Ángel Sánchez-Recalde, MD, PhD · Principal investigator
  • Hospital Clínico Universitario San Carlos
    Madrid, Madrid 28040, Spain
    Not yet recruiting
    • Luis Nombela, MD, PhD · Contact
    • Dr. Luis Nombela, MD, PhD · Principal investigator
  • Hospital Universitario Puerta de Hierro
    Madrid, Madrid 28222, Spain
    Not yet recruiting
    • María del Trigo, MD, PhD · Contact
    • Dra. María del Trigo, MD, PhD · Principal investigator
  • Hospital Universitario Virgen de la Victoria
    Málaga, Málaga 29010, Spain
    Not yet recruiting
    • Juan H. Alonso Briales, MD, PhD · Contact
    • Dr. Juan H. Alonso Briales, MD, PhD · Principal investigator
  • Hospital Álvaro Cunqueiro
    Vigo, Pontevedra 36312, Spain
    Not yet recruiting
    • Rodrigo Estévez-Loureiro, MD, PhD · Contact
    • Dr. Rodrigo Estévez-Loureiro, MD, PhD · Principal investigator
  • Hospital Universitario Central de Asturias (HUCA)
    Oviedo, Principality of Asturias 33011, Spain
    Recruiting
    • Isaac Pascual Calleja, MD, PhD · Contactipascua@live.com · +34985101738
    • Isaac Pascual Calleja · Principal investigator
  • Hospital Clínico Universitario de Valladolid
    Valladolid, Valladolid 47003, Spain
    Not yet recruiting
    • Ignacio Amat-Santos, MD, PhD · Contact
    • Dr. Ignacio Amat-Santos, MD, PhD · Principal investigator
08

References and documents

Publications

  • Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012 Jan;33(2):176-82. doi: 10.1093/eurheartj/ehr352. Epub 2011 Sep 6. PubMed 21900289 ↗
  • Finkelstein DM, Schoenfeld DA. Combining mortality and longitudinal measures in clinical trials. Stat Med. 1999 Jun 15;18(11):1341-54. doi: 10.1002/(sici)1097-0258(19990615)18:113.0.co;2-7. PubMed 10399200 ↗
  • Shuvy M, Maisano F, Strauss BH. Transcatheter Mitral Edge-to-Edge Repair for Treatment of Acute Mitral Regurgitation. Can J Cardiol. 2023 Oct;39(10):1382-1389. doi: 10.1016/j.cjca.2023.05.009. Epub 2023 May 18. PubMed 37209883 ↗
  • Shuvy M, von Bardeleben RS, Grasso C, Raake P, Lurz P, Zamorano JL, Asch F, Kar S, Maisano F; EXPAND Investigators. Safety and efficacy of MitraClip in acutely ill (NYHA Class IV) patients with mitral regurgitation: Results from the global EXPAND study. ESC Heart Fail. 2023 Apr;10(2):1122-1132. doi: 10.1002/ehf2.14273. Epub 2023 Jan 4. PubMed 36599332 ↗
  • Haberman D, Estevez-Loureiro R, Benito-Gonzalez T, Denti P, Arzamendi D, Adamo M, Freixa X, Nombela-Franco L, Villablanca P, Krivoshei L, Fam N, Spargias K, Czarnecki A, Pascual I, Praz F, Sudarsky D, Kerner A, Ninios V, Gennari M, Beeri R, Perl L, Wasserstrum Y, Danenberg H, Poles L, George J, Caneiro-Queija B, Scianna S, Moaraf I, Schiavi D, Scardino C, Corpataux N, Echarte-Morales J, Chrissoheris M, Fernandez-Peregrina E, Di Pasquale M, Regueiro A, Vergara-Uzcategui C, Iniguez-Romo A, Fernandez-Vazquez F, Dvir D, Maisano F, Taramasso M, Shuvy M. Conservative, surgical, and percutaneous treatment for mitral regurgitation shortly after acute myocardial infarction. Eur Heart J. 2022 Feb 12;43(7):641-650. doi: 10.1093/eurheartj/ehab496. PubMed 34463727 ↗
  • Jung RG, Simard T, Kovach C, Flint K, Don C, Di Santo P, Adamo M, Branca L, Valentini F, Benito-Gonzalez T, Fernandez-Vazquez F, Estevez-Loureiro R, Berardini A, Conti N, Rapezzi C, Biagini E, Parlow S, Shorr R, Levi A, Manovel A, Cardenal-Piris R, Diaz Fernandez J, Shuvy M, Haberman D, Sala A, Alkhouli MA, Marini C, Bargagna M, Schiavi D, Denti P, Markovic S, Buzzatti N, Chan V, Hynes M, Mesana T, Labinaz M, Pappalardo F, Taramasso M, Hibbert B. Transcatheter Mitral Valve Repair in Cardiogenic Shock and Mitral Regurgitation: A Patient-Level, Multicenter Analysis. JACC Cardiovasc Interv. 2021 Jan 11;14(1):1-11. doi: 10.1016/j.jcin.2020.08.037. Epub 2020 Oct 14. PubMed 33069653 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.

Of 144 interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 108. This study's planned 29 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2024
First posted
Feb 28, 2024
StartActual
Dec 24, 2024
Primary completionEst.
Jun 16, 2027
CompletionEst.
Jun 16, 2028
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06282042
Lead sponsor
Fundación para la Investigación Biosanitaria del Principado de Asturias
Collaborators
Meditrial Europe Ltd.
Responsible party
Isaac Pascual Calleja (MD, PhD, Fundación para la Investigación Biosanitaria del Principado de Asturias) — Principal investigator
First posted
Feb 28, 2024
Start date
Dec 24, 2024
Primary completion
Jun 16, 2027 (estimated)
Completion
Jun 16, 2028 (estimated)
Last update
Oct 20, 2025

Study contacts

Isaac Pascual MD, PhD
Contact
ipascua@live.com
985101738
Pablo Avanzas, MD, PhD
Contact
avanzas@secardiologia.es
985101738
Isaac Pascual, MD, PhD
principal investigator · Hospital Universitario Central de Asturias

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion